← Back to Clinical Trials
Recruiting NCT01034033

NCT01034033 Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT01034033
Status Recruiting
Phase
Sponsor Stanford University
Condition Breast Cancer
Study Type OBSERVATIONAL
Enrollment 3,300 participants
Start Date 2001-08
Primary Completion 2099-01

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3,300 participants in total. It began in 2001-08 with a primary completion date of 2099-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to try to understand the biology of development of breast, ovarian, fallopian tube, peritoneal or endometrial cancer from persons at high genetic risk for these diseases. The influence of environmental factors on cancer development in individuals and families will be studied. The efficacy of treatments for these diseases will be evaluated.

Eligibility Criteria

Inclusion Criteria: I. Women who have a high risk of developing breast or ovarian cancer due to a known germline mutation in the BRCA1/2, PTEN, CDH1, or TP53 cancer susceptibility genes, or due to strong family history of either breast or ovarian cancer, in the absence of known cancer susceptibility gene mutation. II. Women who are approaching surgery for resection of a pelvic mass, which is considered suspicious for neoplasia by radiologic or clinical criteria; such women may or may not also meet criteria for inclusion in group I.

Contact & Investigator

Central Contact

Meredith Mills

✉ bluett@stanford.edu

📞 (650) 724-5223

Principal Investigator

James M Ford

PRINCIPAL INVESTIGATOR

Stanford University

Frequently Asked Questions

Who can join the NCT01034033 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT01034033 currently recruiting?

Yes, NCT01034033 is actively recruiting participants. Contact the research team at bluett@stanford.edu for enrollment information.

Where is the NCT01034033 trial being conducted?

This trial is being conducted at Stanford, United States.

Who is sponsoring the NCT01034033 clinical trial?

NCT01034033 is sponsored by Stanford University. The principal investigator is James M Ford at Stanford University. The trial plans to enroll 3,300 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology